Kevin Johnson
General Counsel chez Tourmaline Bio, Inc.
Fortune : 1 M $ au 31/03/2024
Profil
Kevin B.
Johnson's current job(s) include being the Chief Regulatory Officer at Tourmaline Sub, Inc. since 2023 and the Chief Regulatory Officer at Tourmaline Bio, Inc. since 2023.
Formerly, Dr. Johnson worked as the Vice President, Global Head- Regulatory & Quality at Sucampo Pharmaceuticals LLC from 2017 to 2018.
He also served as the Global Head-Regulatory Affairs at Novella Clinical, Inc. Thereafter, he held the position of Senior Vice President & Head-Regulatory Affairs at Imara, Inc. from 2018 to 2020.
In 2020, he briefly worked as the Senior Vice President, Head-Regulatory & Quality at Magenta Therapeutics, Inc. and as the Senior Vice President-Regulatory Affairs at Inozyme Pharma, Inc. from 2020 to 2021.
Lastly, he was the Chief Regulatory Officer at Ring Therapeutics, Inc. from 2021 to 2022.
Dr. Johnson's education includes an undergraduate degree from the University of South Florida, an MBA from Kenan-Flagler Business School, and a doctorate from UNC School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,23% | 23/10/2023 | 57 834 ( 0,23% ) | 1 M $ | 31/03/2024 |
Postes actifs de Kevin Johnson
| Sociétés | Poste | Début |
|---|---|---|
Tourmaline Bio, Inc.
 Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The private company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | General Counsel | 19/10/2023 |
Anciens postes connus de Kevin Johnson
| Sociétés | Poste | Fin |
|---|---|---|
Ring Therapeutics, Inc.
 Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA. | General Counsel | 01/12/2022 |
| INOZYME PHARMA, INC. | General Counsel | 01/01/2021 |
| MAGENTA THERAPEUTICS | Public Communications Contact | 01/11/2020 |
| IMARA | General Counsel | 01/09/2020 |
| SUCAMPO PHARMACEUTICALS, INC. | General Counsel | 01/01/2018 |
Formation de Kevin Johnson
| University of South Florida | Undergraduate Degree |
| Kenan-Flagler Business School | Masters Business Admin |
| UNC School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INOZYME PHARMA, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Sucampo Pharmaceuticals, Inc.
 Sucampo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. The company was founded by Ryuji Ueno and Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD. | Health Technology |
Novella Clinical, Inc.
 Novella Clinical, Inc. Miscellaneous Commercial ServicesCommercial Services For over a decade, Novella Clinical has been an active partner in supporting the biopharma and medical device industries with early phase through post-marketing development programs. Although their clinical experience is all-inclusive, the company's eClinical roots enable them to offer services that are specific to their clients' needs, often eliminating the demand to contract with multiple partners. From protocol development through final clinical study report - they integrate deep clinical expertise with industry-leading technologies and a proven approach to support, streamline and expertly resource the entire product development process. It focuses on quality customer service is reflected in their certification by Underwriters Laboratories on meeting global quality standards (ISO 9001:2008). | Commercial Services |
Imara, Inc.
 Imara, Inc. Pharmaceuticals: MajorHealth Technology Imara, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. The company was founded by James Gregg McArthur in 2016 and is headquartered in Brookline, MA. | Health Technology |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Ring Therapeutics, Inc.
Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA. | Health Technology |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The private company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Commercial Services |
